Thebattle for primacy in melanoma treatment is likely to move to the early, adjuvant (post-surgical) setting, following the release of strong data for Bristol-Myers Squibb Co.'s immunotherapy Opdivo and Novartis AG/GlaxoSmithKline PLC'sBRAF and MEK inhibitors Tafinlar and Mekinist, based on full Phase III results presented at the European Society of Medical Oncology (ESMO) annual meeting.
Bristol's PD-1 inhibitor Opdivo and Novartis/Glaxo's Tafinlar (dabrafenib)/Mekinist (trametinib) combination both dramatically and significantly increased relapse-free survival (RFS) rates and...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)